Thromboembolism related to a Port-a-Cath device in a patient with cystic fibrosis

B Yung, J S Elborn, I A Campbell, Y Summers, M Beckles, A A Woodcock

Abstract
The case is described of a potentially life threatening complication relating to the use of a totally implantable venous access device (Port-a-Cath) in a 28 year old patient with cystic fibrosis. The device was inserted in 1990 and used repeatedly for antibiotic therapy without any complications. In 1995, during assessment for double lung transplantation, a 3 cm thrombus was found at the tip of the catheter in the right atrium. Embolisation of the thrombus to the pulmonary arteries occurred after the infusion of recombinant tissue plasminogen activator (rt-PA). Thrombus formation may be associated with totally implantable venous access devices and thromboembolism may occur following the use of thrombolytic agents in the treatment of such thrombosis.

Keywords: cystic fibrosis, totally implantable venous access devices, thromboembolism.

Totally implantable venous access devices are used in oncological patients and in patients with cystic fibrosis. These devices provide safe effective means of intermittent venous access and are well accepted by patients. We report a potentially life threatening complication related to the use of a Port-a-Cath device in a patient with cystic fibrosis.

Case report
A 28 year old patient with cystic fibrosis (delta F508 heterozygous), who had deteriorated after the birth of her son in 1990, was being assessed for double lung transplantation. She frequently required intravenous antibiotics for chronic Pseudomonas aeruginosa infection of her lungs and venous access became increasingly difficult. In June 1990 a Port-a-Cath was implanted via the right cephalic vein and she subsequently had many antibiotic courses through this device without complication. There was no previous history or family history of thromboembolism and she was not taking the contraceptive pill.

In January 1995 she was referred for assessment for lung transplantation. Her forced expiratory volume in one second (FEV₁) was 0.76 l (26% predicted) and her body mass index was 19.1 kg/m². Her clotting screen was normal. A routine two dimensional echocardiogram revealed a 3 cm clot at the catheter tip of the Port-a-Cath in the right atrium. The device was functioning well and the patient was asymptomatic. A bolus dose of 50 mg recombinant tissue plasminogen activator (rt-PA) was given intravenously over an hour on two occasions during the next 16 hours in an attempt to lyse the clot and she was then commenced on intravenous heparin infusion. She remained well until three hours after the last dose of rt-PA when she became acutely unwell and complained of pleuritic chest pain with severe dyspnoea of sudden onset.

On examination she was unwell with tachypnoea and tachycardia. Her blood pressure was 120/90 mm Hg and oxygen saturation was 92% on oxygen at 8 l/min via nasal cannulae (her normal oxygen saturation was 92% on air). Her electrocardiogram and chest radiograph were unchanged. A diagnosis of acute pulmonary embolism was made. Her clotting status was checked and a further heparin bolus dose was given because of an inadequate KCCT ratio of 1.05. A computed tomographic (CT) contrast enhanced pulmonary angiogram confirmed the presence of clots in the right main pulmonary artery (fig 1) and the artery to the right lower lobe. A repeat echocardiogram showed no evidence of the clot at the tip of the catheter. The patient’s condition was stable and she continued to receive heparin and subsequently warfarin.

Two days later she became more dyspnoeic with production of purulent sputum. Intravenous antibiotics were started and she was also given a 50 mg dose of rt-PA via her Port-a-Cath. A repeat CT pulmonary angiogram performed 24 hours later showed persistence of the clots in the pulmonary arteries. She was commenced on streptokinase infusion (250 000 units over 30 minutes) but developed an anaphylactic reaction three minutes into the infusion and the infusion was stopped. Following repeat clotting studies two further doses of rt-PA were given over the next six hours but a repeat CT pulmonary angiogram 24 hours later was unchanged. She was then treated with four doses of intravenous urokinase (4400 units/kg on each occasion, given over 30 minutes, with hydrocortisone cover) over the next 18 hours. Her clinical condition improved and a repeat CT pulmonary angiogram performed 24 hours later revealed resolution of clot in the right main pulmonary artery and in the artery to the right lower lobe. She was discharged three days later on warfarin. A repeat echocardiogram six weeks later revealed no evidence of a recurrence of the clot on the Port-a-Cath which still remains fully functional. Following this case, we elected to perform two dimensional echocardiograms on all 11 of our patients with cystic fibrosis with Port-a-Cath devices and no further case of thrombosis was identified.

Discussion
Port-a-Cath devices have been used in oncological patients since 1982 and are as-
Transverse myelitis in cystic fibrosis

Figure 1: Computed tomographic pulmonary angiogram showing a marked filling defect in the right main pulmonary artery (arrowed).

Transverse myelitis: a reversible complication of bronchial artery embolisation in cystic fibrosis

K L Fraser, H Grosman, R H Hyland, D E Tullis

Abstract

The case history is presented of a young woman with cystic fibrosis and life-threatening haemoptysis. Angiography revealed enlarged bronchial vessels, one of which supplied the contralateral lung. Transverse myelitis developed following bronchial artery embolisation but recovery was rapid and nearly complete. Haemoptysis did not recur during four years of follow up.

(Thorax 1997;52:99–101)

Keywords: cystic fibrosis, bronchial artery, embolisation, transverse myelitis.

A 28-year-old woman who was diagnosed with cystic fibrosis in infancy had moderate lung disease (forced vital capacity 75% predicted, forced expiratory volume in one second 61% predicted) and was colonised with Pseudomonas aeruginosa and Burkholderia cepacia. She was generally well with few hospital admissions for pulmonary exacerbations. In July 1991 she developed haemoptysis associated with a pulmonary exacerbation, resulting in a significant fall in her haemoglobin level. She improved with conservative treatment.

Haemoptysis recurred in October 1991 and her haemoglobin fell from 13.4 g/dl to 11.4 g/dl.

Thrombolytic agents are effective in the treatment of pulmonary embolism, accelerating clot lysis, hastening pulmonary tissue perfusion, reversing right heart failure, and improving pulmonary capillary blood volume. They are particularly useful in the treatment of pulmonary embolism when the haemodynamic status is compromised. A serial contrast enhanced helical CT pulmonary angiogram can be used for diagnosis and monitoring the subsequent response to thrombolytic therapy. We suggest that, in patients with totally implantable venous access devices, thromboembolism should be considered as a differential diagnosis should a patient develop sudden chest pain and dyspnoea, especially if this occurs soon after the infusion of thrombolytic agents or heparin.

By was supported by the Cystic Fibrosis Trust. We would like to thank staff at the ECG department, Llandough Hospital for performing the echocardiograms.


Division of Respiratory Medicine
K L Fraser
R H Hyland
D E Tullis

Department of Radiology
H Grosman

The Wellesley Hospital,
University of Toronto,
Toronto, Ontario M4Y 1JS, Canada

Correspondence to:
Dr D E Tullis.

Received 14 December 1995
Returned to authors
29 March 1996
Revised version received
12 August 1996
Accepted for publication
3 October 1996
The right fifth intercostal artery, when injected with contrast, filled more proximally positioned intercostal vessels through communicating branches parallel to the spine until eventually filling an abnormally enlarged nonbronchial systemic artery supplying the right upper lobe. This large abnormal vessel could only be embolised remotely via the right fifth intercostal artery. The catheter became wedged into this vessel during the lengthy embolisations and there was angiographic “hold up” or stagnation of contrast medium in the proximal intercostal vessels on “control” injections into the right fifth intercostal artery (figs 1–3).

The left thyrocervical trunk gave rise to an enlarged bronchial vessel which crossed the midline and supplied the right lower lobe (a rare congenital anomaly). Since this was a very large vessel, it was embolised with a combination of Ivalon and absorbable gelatin sponge particles (Gelfoam; Upjohn, Ontario, Canada). A fourth enlarged bronchial artery arising from the right thyrocervical trunk and supplying the right mid lung was cannulated and embolised with the same combination.

A 5 French end hole embolisation Cobra catheter (Cook Inc, Bloomington, Indiana, USA) was used for the first two vessels embolised and a 5 French HIH (head hunter) catheter (Cook Inc) for the enlarged bronchial arteries arising from each of the thyrocervical trunks. The procedure lasted approximately four hours and a total of 300 ml of non-ionic contrast medium was injected. Digital subtraction angiography was used entirely during the procedure in an attempt to keep the volume of contrast medium used to a minimum and successfully embolised to assess better the vascular supply to the cord.

No obvious vascular supply to the cord, however, was visualised during the entire study. One limitation might have been the lack of communicating branches with other intercostal vessels and no visualisation of vascular supply to the spinal cord.

She required a total of four units of blood. Conservative treatment was not successful and three days after admission she was scheduled for bronchial arteriography and embolisation. On the morning of the scheduled procedure she had massive haemoptysis with respiratory compromise necessitating intubation. Bronchial artery angiography was performed. The first artery recognised as a bronchial artery arose from the left side of the aorta at around T7. As embolisation was performed using polyvinyl alcohol microspheres 300–600 μm (Ivalon; Locam Medical Distributors, Laboratories Nycamed, Paris, France) more and more enlarged collateral vessels supplying the left lung became apparent and were further embolised.

The following morning the patient complained of paralysis of the left leg and was found to have right sided sensory disturbance to the level of T4. Posterior column function was intact, compatible with a diagnosis of transverse myelitis.

Treatment was initiated immediately with intravenous methylprednisolone 125 mg daily for three days and there was rapid neurological improvement. At the time of discharge 25 days later some sensory deficit and minimal foot drop persisted. With rehabilitation therapy no discernible motor weakness remained, although neurological examination revealed re-
Transverse myelitis in cystic fibrosis

Introduction

Transverse myelitis is a well recognised complication of arteriography and is a theoretical risk of bronchial artery embolisation because of the anatomical variation of a shared origin of bronchial arteries with intercostal vessels which supply radiculomedullary branches to the anterior spinal circulation. However, there are no reports in the literature of transverse myelitis following bronchial artery embolisation. Kardjiev et al reported five cases in which similar neurological events followed the injection of contrast medium into the right fifth intercostal artery. The procedures were carried out for diagnostic purposes only and a different contrast medium (ionic) from ours was used. All patients made a full recovery although it took almost three months for one patient’s symptoms to resolve.

Our patient is similar in that contrast material was injected into the fifth right intercostal artery and in the subsequent neurological course. Given the delayed onset of the neurological event and the reversible nature of the lesion, and given the lack of visualisation of the anterior spinal artery complex and the amount of embolic material used, we postulate that this, too, is a case of a contrast-induced spinal cord lesion. This may have been promoted by the wedging of the catheter into the right fifth intercostal origin and the persistence of contrast material in this vessel and its branches during this lengthy, although life saving, procedure.

Discussion

The bronchial artery circulation is quite variable and complex. Arterial origins arise mainly from the thoracic aorta or its branches. Up to 20% arise from various other vessels and the remaining 10% originate from the anterior surface of the aortic arch. In conditions of chronic inflammation such as cystic fibrosis and tuberculous bronchiectasis, the bronchial circulation expands greatly. The same vessels that supply the bronchial arteries may also supply the oesophagus, mediastinal lymph nodes, and the spinal arteries through a complex anastomotic network. This expanded systemic circulation is the primary source of bleeding in haemoptysis. Many patients with cystic fibrosis have undergone bronchial artery embolisation for treatment of haemoptysis. We are aware of one previous case in which an hypertrophied bronchial vessel has supplied the contralateral lung.

In that report, the patient had undergone multiple previous embolisations and the authors hypothesised that the previous interventions may have contributed to the enlargement of the vessel. Our patient had no previous history of embolisation, suggesting that this uncommon circulation may arise simply as a result of chronic inflammation.

Transverse myelitis is a well recognised complication of arteriography and is a theoretical risk of bronchial artery embolisation because of the anatomical variation of a shared origin of bronchial arteries with intercostal vessels which supply radiculomedullary branches to the anterior spinal circulation. However, there are no reports in the literature of transverse myelitis following bronchial artery embolisation. Kardjiev et al reported five cases in which similar neurological events followed the injection of contrast medium into the right fifth intercostal artery. The procedures were carried out for diagnostic purposes only and a different contrast medium (ionic) from ours was used. All patients made a full recovery although it took almost three months for one patient’s symptoms to resolve.